Navigation Links
China Sky One Medical Receives GMP Re-Certification

HARBIN, China, May 27 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that its Tian Long Pharmaceutical Company ("Tian Long") subsidiary successfully obtained renewal of its Good Manufacturing Practices Certificate for Pharmaceutical Products ("GMP Certificate") from the State Food and Drug Administration (SFDA) in China. The new certificate will be valid until May 2015.

According to the National Medicine Administration Law of the PRC, all pharmaceutical manufacturers are required to renew their GMP Certificates every five years. SFDA's examination committee visited Tian Long in April to review its supply chain management practices, including quality control system test, inspect its GMP management process, production records for its five production lines, quality test record and laboratory management.

"Given the extensive scope of the inspection and examination, we are very proud to pass the examination in just one round and successfully renewed the GMP Certificate for Tian Long," said Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "China Sky One Medical has built a solid track record of adhering to the highest quality control standards, thanks to our talented and dedicated executives and professional teams in the quality control and production departments."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the renewal of GMP Certificate. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-8703-2617

    Investor Relations Contact:
     CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353

SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
2. China BCT Reports First Quarter 2010 Results
3. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
4. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
5. China Biologic Products Schedules Conference Call to Discuss First Quarter 2010 Results
6. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
7. China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit
8. China Sky One Medical Provides Sales Forecast for 13 New Products
9. China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity
10. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
11. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... relationship marketing company specializing in scientifically backed, age-defying products, is featured as ... which highlights the exponential success and unrivaled opportunities that Nerium provides. Success ...
(Date:12/1/2015)... 2015 Cepheid (Nasdaq: CPHD ) today ... Piper Jaffray Healthcare Conference in New York ... reaffirming its outlook for the fourth quarter of 2015 ... discussing longer term business model expectations. John ... continue to be the fastest growing company of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... meeting this month and Dr. J. Kyle Mathews will join fellow ... the new single site hysterectomy. , An experienced urogynecologist, founder of Plano Urogynecology ...
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
Breaking Biology Technology:
(Date:11/30/2015)... , Nov. 30, 2015  BIOCLAIM announced ... finalist in this year,s Fierce Innovation Awards:  Healthcare Edition, ... FierceHealthIT , FierceHealthcare , ... as a finalist in the category of "Privacy ... --> --> ...
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
Breaking Biology News(10 mins):